Prostate biopsy coding in 2026: the new 55706-55715 code family.
CPT 55700 — the single code that covered a prostate needle biopsy by any approach for over a decade — was deleted effective January 1, 2026. It's replaced by a revised 55705 plus nine new codes, 55706 through 55715, that split the procedure by approach, imaging method, and targeting type, with imaging guidance now built directly into each code's descriptor. If your superbill or scrubber still references 55700, every claim under it denies on invalid code before medical necessity is ever considered; if your coders are stacking an imaging-guidance code on top of a new biopsy code the way they used to, that claim is due for recoupment. This guide, part of our read the full urology billing guide, walks through the complete code family, the bundling trap, and how to actually crosswalk an old superbill.
Key takeaways
- 55700 no longer exists. Nine new codes (55706–55715) plus a revised 55705 replace it, split along three axes: transrectal vs. transperineal approach, imaging method, and systematic vs. targeted sampling.
- Imaging guidance is bundled into the code, not billed separately. 76872 and 76942 alongside any of 55707–55714 is a stacking error — it denies as bundled or gets recouped, it doesn't add revenue.
- Code selection now depends on documentation that "prostate biopsy performed" never used to require. The operative note has to name the approach and the imaging method explicitly, or no single code in the family is supportable on audit.
- There's no one-to-one crosswalk from 55700. Mapping the old superbill onto the new family requires pulling actual operative notes, not a global find-and-replace.
The full 2026 code family
The CPT Editorial Panel didn't just split 55700 in two — it built a matrix. Every code in the family answers the same three questions: which approach, what imaging (if any), and whether the sampling is systematic, targeted, or both in the same session. Descriptions below are paraphrased, not reproduced from the CPT Professional edition.
| Code | Approach | Imaging / targeting |
|---|---|---|
55705 | Any approach | No imaging guidance (revised existing code, not new for 2026) |
55706 | Transperineal | Stereotactic template saturation sampling |
55707 | Transrectal | Ultrasound-guided systematic sampling (sextant / ultrasound-localized lesions), no MRI fusion |
55708 | Transrectal | Ultrasound-guided systematic sampling combined with MRI-fusion targeting of a lesion, same session |
55709 | Transperineal | Ultrasound-guided systematic sampling (sextant / ultrasound-localized lesions), no MRI fusion |
55710 | Transperineal | Ultrasound-guided systematic sampling combined with MRI-fusion targeting, same session |
55711 | Transrectal | MRI-ultrasound fusion, targeted lesion(s) only — no systematic cores |
55712 | Transperineal | MRI-ultrasound fusion, targeted lesion(s) only — no systematic cores |
55713 | Approach-agnostic | In-bore CT/MRI guided, systematic plus additional targeted lesion(s) |
55714 | Approach-agnostic | In-bore CT/MRI guided, targeted lesion(s) only |
55715 | — | Add-on: each additional MRI-fusion or in-bore targeted lesion beyond the first, listed with the primary biopsy code |
Two structural points to build into the charge master. First, 55713 and 55714 are approach-agnostic on paper — the in-bore technique doesn't distinguish transrectal from transperineal the way the ultrasound-fusion codes do, so don't force an approach modifier onto them that the descriptor doesn't call for. Second, 55715 is an add-on code only; it is never billed as a stand-alone line, and it only makes sense stacked against 55708, 55710, 55711, 55712, 55713, or 55714 — any code where MRI-fusion or in-bore targeting is actually part of the service. Appending 55715 to 55707 or 55709, which carry no MRI-fusion component, doesn't match the clinical scenario the add-on code describes.
Choosing the right code: the three questions
Every claim in this family gets decided by the same three-question sequence, in order. Skipping straight to "was it transrectal or transperineal" without confirming imaging method first is how a coder lands on the wrong code even when the approach was captured correctly.
- 1What imaging, if any, guided the biopsy? None supports only 55705. Ultrasound alone, with no MRI fusion, points to 55707 or 55709. MRI-ultrasound fusion points to 55708, 55710, 55711, or 55712 depending on what else is true. In-bore CT or MRI guidance points to 55713 or 55714.
- 2Which approach was used — transrectal or transperineal? This splits every ultrasound- and fusion-guided pair: 55707 vs. 55709, 55708 vs. 55710, 55711 vs. 55712. The operative note has to state it explicitly; "prostate biopsy performed" alone doesn't support either half of the pair.
- 3Was the sampling systematic, targeted, or both in the same session? Systematic-only with no fusion targeting is 55707/55709. Systematic combined with MRI-fusion targeting in the same session is 55708/55710. Fusion-targeted lesions with no systematic cores at all is 55711/55712. Get this axis wrong and the code overstates or understates what was actually sampled, which matters on medical necessity review as much as on payment.
Documentation carries more weight in this family than it did under 55700, because a single generic operative note used to support one code no matter how the biopsy was actually performed. Now, a note that doesn't name the approach and the imaging method doesn't cleanly support any single code in the family — and a coder guessing from an incomplete note is a compliance exposure the practice doesn't need to carry.
The bundled-imaging billing trap
This is the single most expensive habit left over from the 55700 era. Under the old code, imaging guidance genuinely was billed separately — 76872 for transrectal ultrasound guidance, 76942 for imaging guidance during needle placement, appended alongside 55700 to capture the imaging work. That pattern doesn't carry over to 2026, because every ultrasound- and MRI-guided code in the new family already has the imaging method written into its own descriptor. The guidance work isn't a separate service anymore; it's part of what the biopsy code itself describes.
- Bill the single biopsy code that already reflects the imaging method used — 55707 for a transrectal ultrasound-guided systematic biopsy, on its own, with nothing else appended for the guidance itself.
- Reserve 76872/76942 for genuinely separate procedures unrelated to that same-session prostate biopsy, if such a scenario actually arises — not as a routine add-on to any 5570x code.
- Billing 55708 plus 76872 on the same claim, the same date, for the same biopsy — that's not two services, it's one service billed twice.
- Assuming a claim that paid once under this pattern is safe going forward — a claim that pays despite the stacking error is exactly the kind post-payment review recoups later, with interest and a look-back period attached.
The financial logic runs the opposite direction from what it looks like at first glance: stacking the old imaging codes on top of the new biopsy codes isn't capturing extra reimbursement the payer owes you, it's double-billing a component the new code already prices in. Scrub for this specific pair — any 5570x code plus 76872 or 76942, same date — before the claim goes out, not after a payer's own edit catches it.
ICD-10 specificity for medical necessity
The indication drives coverage as much as the code selection does. Codes below verified live against the FY2026 ICD-10-CM code set.
| Scenario | Code | Note |
|---|---|---|
| Elevated PSA, no prior cancer diagnosis | R97.20 | The most common driver for an initial biopsy; a symptom-only or unspecified code doesn't substitute for the actual lab-driven indication |
| Rising PSA after prior prostate cancer treatment | R97.21 | Use for a surveillance or recurrence-workup biopsy after prostatectomy or radiation — not the pre-treatment elevated-PSA code |
| Screening biopsy without an abnormal finding driving it | Z12.5 | Rare as the sole justification for a biopsy specifically, more common as a secondary code alongside the clinical indication |
| Established prostate cancer, surveillance or restaging biopsy | C61 | Active surveillance biopsies on a known cancer diagnosis code to C61, not to a PSA or screening code |
| Indeterminate finding on prior imaging or pathology | D40.0 | Neoplasm of uncertain behavior of prostate — supports a confirmatory or repeat biopsy where the prior result wasn't definitive |
The pattern that trips practices up: an MRI-fusion biopsy (55708/55710/55711/55712) is frequently ordered specifically because a prostate MRI already flagged a PI-RADS lesion, and the claim needs a diagnosis code that reflects that finding, not a generic elevated-PSA code alone, when the payer's medical necessity policy expects it. Check your MAC's specific biopsy coverage article for the exact accepted code list before assuming R97.20 alone clears every payer's bar.
Crosswalking an old superbill
There's no clean one-to-one mapping from 55700 to a single 2026 code, and that's the part most transition checklists skip over. 55700 covered every approach and every imaging method under one line item; the new family requires knowing which variant was actually performed for each historical claim pattern in your practice. A blanket find-and-replace from 55700 to any single new code will be wrong for a meaningful share of your cases.
- 1Pull a sample of recent operative notes, not billing data alone. The claim under 55700 doesn't tell you the approach or imaging method that was used — only the note does.
- 2Tag each sampled case against the three-question sequence above and build a frequency count: what share of your practice's biopsies are transrectal ultrasound-only, what share are MRI-fusion, what share are transperineal.
- 3Rebuild the superbill or EHR order set as explicit checkboxes for approach and imaging method — not free text, and not a single "prostate biopsy" line item. The physician selects both variables at the time of the note, and the code follows automatically.
- 4Audit the first 90 days of claims under the new codes specifically for the 76872/76942 stacking error above — it's the single most common artifact of an incomplete crosswalk, because old scrubber rules built around 55700 often don't know the new codes already include imaging.
If a claim already denied on 55700 for a 2026 date of service, don't appeal it — it's not a documentation gap, it's an invalid code, and no appeal argument reverses that. Rebill with the correct code from the operative note. Save appeal effort for claims where the code was right and the denial reason was something else, like a diagnosis specificity mismatch.
Related BPH and endoscopic work
Prostate biopsy findings frequently drive the next procedure in the same patient's chart. When a biopsy comes back negative but LUTS persist, the workup often moves toward a BPH device procedure — see our BPH Procedure Coding: UroLift, Rezum, TURP, Laser and Aquablation guide for the full code set there, including a similar bundling trap on the imaging side. And because a biopsy is frequently performed at the same visit as diagnostic cystoscopy in a broader urologic workup, our Cystoscopy CPT Coding: 52000-52356 Explained guide covers exactly when that combination is billable together and when it isn't.
Still billing off a pre-2026 prostate biopsy superbill?
We'll audit a sample of your recent prostate biopsy claims, flag any 55700 holdovers or 76872/76942 stacking errors, and show what's recoverable before it becomes a recoupment.
Frequently asked questions
Can we still bill 76872 or 76942 alongside the new prostate biopsy codes?
No. Every 2026 biopsy code that involves imaging already has the guidance method built into its own descriptor, so 76872 (transrectal ultrasound guidance) and 76942 (imaging guidance for needle placement) are components of the biopsy code, not separately payable add-ons. Billing either one alongside 55707 through 55714 is billing a component twice, and it will either deny as bundled or get recouped on post-payment review once a payer's edit software catches the pattern.
What's the difference between billing 55707 and 55711 for a transrectal biopsy?
55707 covers an ultrasound-guided systematic biopsy through the transrectal approach with no MRI-fusion targeting involved — the standard sextant or template pattern. 55711 covers a transrectal biopsy where MRI-ultrasound fusion targets specific lesions only, with no systematic cores taken alongside them. If the case combines both a systematic pattern and MRI-fusion targeting of a lesion in the same session through the transrectal approach, neither code fits alone — that combination is 55708, not a double-billing of 55707 plus 55711.
Our superbill still lists 55700 — how do we crosswalk it to the new codes?
There is no single one-to-one replacement, which is exactly why a blanket find-and-replace on the superbill doesn't work. Pull the operative note for a sample of recent cases and confirm two data points for each: the approach (transrectal or transperineal) and the imaging method actually used (none, ultrasound alone, MRI-fusion, or in-bore). Build the new superbill or order set around those two variables as explicit checkboxes, not free text, so the coder and the physician are both selecting the same code every time instead of guessing from a vague note.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.